These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30777794)

  • 21. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
    Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M;
    Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.
    Rosiñol L; Oriol A; Rios R; Sureda A; Blanchard MJ; Hernández MT; Martínez-Martínez R; Moraleda JM; Jarque I; Bargay J; Gironella M; de Arriba F; Palomera L; González-Montes Y; Martí JM; Krsnik I; Arguiñano JM; González ME; González AP; Casado LF; López-Anglada L; Paiva B; Mateos MV; San Miguel JF; Lahuerta JJ; Bladé J
    Blood; 2019 Oct; 134(16):1337-1345. PubMed ID: 31484647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
    Sahebi F; Frankel PH; Farol L; Krishnan AY; Cai JL; Somlo G; Thomas SH; Reburiano E; Popplewell LL; Parker PM; Spielberger RT; Kogut NM; Karanes C; Htut M; Ruel C; Duarte L; Murata-Collins JL; Forman SJ
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):486-92. PubMed ID: 22198542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.
    Einsele H; Engelhardt M; Tapprich C; Müller J; Liebisch P; Langer C; Kropff M; Mügge LO; Jung W; Wolf HH; Metzner B; Hart C; Gramatzki M; Hertenstein B; Pfreundschuh M; Rösler W; Fischer T; Maschmeyer G; Kanz L; Hess G; Jäger E; Bentz M; Dürk HA; Salwender H; Hebart H; Straka C; Knop S
    Br J Haematol; 2017 Nov; 179(4):586-597. PubMed ID: 28961309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
    Attal M; Lauwers-Cances V; Hulin C; Leleu X; Caillot D; Escoffre M; Arnulf B; Macro M; Belhadj K; Garderet L; Roussel M; Payen C; Mathiot C; Fermand JP; Meuleman N; Rollet S; Maglio ME; Zeytoonjian AA; Weller EA; Munshi N; Anderson KC; Richardson PG; Facon T; Avet-Loiseau H; Harousseau JL; Moreau P;
    N Engl J Med; 2017 Apr; 376(14):1311-1320. PubMed ID: 28379796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience.
    Tanimura A; Hirai R; Nakamura M; Takeshita M; Togano T; Sekine R; Hagiwara S; Miwa A
    Gan To Kagaku Ryoho; 2020 May; 47(5):789-796. PubMed ID: 32408321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.
    Dhakal B; Szabo A; Chhabra S; Hamadani M; D'Souza A; Usmani SZ; Sieracki R; Gyawali B; Jackson JL; Asimakopoulos F; Hari PN
    JAMA Oncol; 2018 Mar; 4(3):343-350. PubMed ID: 29302684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two cycles of the PS-341/bortezomib, adriamycin, and dexamethasone combination followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.
    Lee JH; Lee JH; Kim DY; Kim SD; Choi Y; Kang YA; Seol M; Lee KH
    Eur J Haematol; 2012 Jun; 88(6):478-84. PubMed ID: 22364526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma.
    Cavo M; Pantani L; Pezzi A; Petrucci MT; Patriarca F; Di Raimondo F; Marzocchi G; Galli M; Montefusco V; Zamagni E; Gamberi B; Tacchetti P; Brioli A; Palumbo A; Sonneveld P
    Leukemia; 2015 Dec; 29(12):2429-31. PubMed ID: 26442610
    [No Abstract]   [Full Text] [Related]  

  • 31. Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.
    Takashima S; Miyamoto T; Kadowaki M; Ito Y; Aoki T; Takase K; Shima T; Yoshimoto G; Kato K; Muta T; Shiratsuchi M; Takenaka K; Iwasaki H; Teshima T; Kamimura T; Akashi K
    Int J Hematol; 2014 Aug; 100(2):159-64. PubMed ID: 24928523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
    Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
    BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.
    Morgan GJ; Davies FE; Gregory WM; Bell SE; Szubert AJ; Navarro Coy N; Cook G; Feyler S; Johnson PR; Rudin C; Drayson MT; Owen RG; Ross FM; Russell NH; Jackson GH; Child JA;
    Haematologica; 2012 Mar; 97(3):442-50. PubMed ID: 22058209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study.
    Ahn SY; Jung SH; Joo YD; Lee WS; Lee SM; Choi CW; Kim SJ; Kim K; Lee JJ;
    Ann Hematol; 2014 Sep; 93(9):1571-7. PubMed ID: 24728664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
    Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.
    Stadtmauer EA; Pasquini MC; Blackwell B; Hari P; Bashey A; Devine S; Efebera Y; Ganguly S; Gasparetto C; Geller N; Horowitz MM; Koreth J; Knust K; Landau H; Brunstein C; McCarthy P; Nelson C; Qazilbash MH; Shah N; Vesole DH; Vij R; Vogl DT; Giralt S; Somlo G; Krishnan A
    J Clin Oncol; 2019 Mar; 37(7):589-597. PubMed ID: 30653422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy and tolerability of bortezomib, thalidomide, and dexamethasone induction therapy with a thalidomide dose step-up strategy in patients with newly diagnosed multiple myeloma: A prospective observational study.
    Liao PW; Lu HJ; Chen TC; Lin HC; Shih YH; Teng CJ
    Cancer Rep (Hoboken); 2024 May; 7(5):e2102. PubMed ID: 38775249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of efficacy, safety, patients' quality of life, and doctors' occupational stress between lenalidomide-based and bortezomib-based induction in patients with newly diagnosed multiple myeloma.
    Xu L; Liu J; Huang B; Kuang L; Gu J; Chen M; Zou W; Li J
    Cancer Med; 2021 Mar; 10(5):1656-1667. PubMed ID: 33527753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma.
    Mori Y; Takizawa J; Katsuoka Y; Takezako N; Nagafuji K; Handa H; Kuroda J; Sunami K; Kamimura T; Ogawa R; Kikushige Y; Harada M; Akashi K; Miyamoto T;
    Cancer Sci; 2024 Jun; 115(6):2002-2011. PubMed ID: 38498976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new standard of care in newly diagnosed multiple myeloma.
    Richardson PG
    Lancet; 2010 Dec; 376(9758):2043-4. PubMed ID: 21146204
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.